Domain Therapeutics appoints chair of board
This article was originally published in Scrip
Executive Summary
Strasbourg, France-based Domain Therapeutics, a biopharmaceutical company specializing in the development of new drug candidates targeting G protein-coupled receptors (GPCRs), has named Dr Youssef L Bennani chair of its board of directors. Dr Bennani is currently site head and vice-president of R&D at Vertex Pharmaceuticals' site in Laval, Quebec. He replaces Sam Eletr who held the position of chair of the board from November 2008 to April 2014. Mr Eletr remains a contributing shareholder of Domain.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.